Prenatal exposure to β2-adrenergic receptor agonists and risk of autism spectrum disorders

Table 4 Adjusted ORs and 95% CIs for ASDs associated with duration of exposure to B2AR agonists during pregnancy

Exposure^a	No. (%)		Adjusted OR (95% CI)^b	Adjusted OR (95% CI)^c
Exposure^a	ASD case (n = 291)	Control (n = 284)	Adjusted OR (95% CI)^b	Adjusted OR (95% CI)^c
Terbutaline
>2 Days^d	8 (2.75)	2 (0.704)	4.1 (0.8–22.4)	4.4 (0.8–24.6)
1–2 Days	24 (8.25)	19 (6.69)	1.0 (0.5–2.0)	1.0 (0.5–2.0)
Albuterol
>21 Days^e	14 (4.81)	11 (3.87)	1.3 (0.5–3.1)	1.4 (0.6–3.5)
≤21 Days	13 (4.47)	9 (3.17)	1.2 (0.5–3.1)	1.3 (0.5–3.4)

B2AR β2-adrenergic receptor; OR odds ratio; CI confidence interval
^aThe reference group had no exposure to any B2AR agonists from 30 days before conception through delivery; cut-points for duration based on distribution of length of exposure among control mothers
^bOdds ratios were adjusted for maternal education, maternal age, birth type, gestational age, parity, birth hospital, birth year, and sex
^cOdds ratios were adjusted for variables listed above in addition to asthma and preterm labor indications
^dAll women with >2 days of exposure were exposed for this duration in the third trimester
^e>21 Days of exposure occurred across multiple trimesters

ISSN: 1866-1955